AbbVie EBITDA 2010-2022 | ABBV

AbbVie annual and quarterly EBITDA history from 2010 to 2022. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • AbbVie EBITDA for the quarter ending September 30, 2022 was $6.808B, a 5.83% increase year-over-year.
  • AbbVie EBITDA for the twelve months ending September 30, 2022 was $25.978B, a 3.05% increase year-over-year.
  • AbbVie 2021 annual EBITDA was $26.445B, a 48.28% increase from 2020.
  • AbbVie 2020 annual EBITDA was $17.834B, a 18.89% increase from 2019.
  • AbbVie 2019 annual EBITDA was $15B, a 84.09% increase from 2018.
AbbVie Annual EBITDA
(Millions of US $)
2021 $26,445
2020 $17,834
2019 $15,000
2018 $8,148
2017 $11,046
2016 $10,529
2015 $8,373
2014 $4,197
2013 $6,561
2012 $6,967
2011 $4,892
2010 $5,901
2009 $5,629
AbbVie Quarterly EBITDA
(Millions of US $)
2022-09-30 $6,808
2022-06-30 $5,347
2022-03-31 $6,770
2021-12-31 $7,053
2021-09-30 $6,433
2021-06-30 $6,641
2021-03-31 $6,318
2020-12-31 $5,818
2020-09-30 $5,547
2020-06-30 $2,307
2020-03-31 $4,162
2019-12-31 $4,465
2019-09-30 $3,120
2019-06-30 $3,902
2019-03-31 $3,513
2018-12-31 $-1,999
2018-09-30 $3,594
2018-06-30 $3,205
2018-03-31 $3,348
2017-12-31 $2,151
2017-09-30 $3,073
2017-06-30 $3,041
2017-03-31 $2,781
2016-12-31 $2,642
2016-09-30 $2,665
2016-06-30 $2,676
2016-03-31 $2,546
2015-12-31 $2,374
2015-09-30 $2,112
2015-06-30 $2,042
2015-03-31 $1,845
2014-12-31 $-222
2014-09-30 $1,152
2014-06-30 $1,717
2014-03-31 $1,550
2013-12-31 $1,735
2013-09-30 $1,605
2013-06-30 $1,689
2013-03-31 $1,532
2012-12-31 $2,130
2012-09-30 $1,823
2012-06-30 $1,717
2012-03-31 $1,297
2011-12-31 $-5,562
2011-09-30 $4,724
2011-06-30 $4,592
2011-03-31 $1,139
2010-12-31
2009-12-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $289.429B $56.197B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $467.679B 18.00
Eli Lilly (LLY) United States $356.089B 44.94
Novo Nordisk (NVO) Denmark $287.171B 37.66
Pfizer (PFE) United States $285.774B 7.81
Merck (MRK) United States $278.995B 14.37
Novartis AG (NVS) Switzerland $199.112B 15.00